


amendment. If the Examiner believes it to be helpful, she is invited to contact the undersigned representative by telephone at (312) 913-0001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Dated: September 20, 2002

By: 
Donald L. Zuhn, Ph.D.
Reg. No. 48,710

AMENDMENTS TO THE SPECIFICATIONMarked Up Version of Specification under 37 C.F.R. 1.121(b)(1)(iii)

Please amend the abstract to read as follows:

~~At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 30kDa and 40kDa TNF inhibitors from urine is disclosed. The deglycosylated form of the 30kDa TNF inhibitor and 40kDa TNF inhibitor are described as being active against TNF. The 40kDa TNF inhibitor is active against both TNF alpha and TNF beta. The amino acid sequence of the 30kDa TNF inhibitor and the 40kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant DNA methods are also disclosed. The present invention provides nucleic acid molecules encoding a TNF inhibitor or a fragment thereof having at least one non-native cysteine residue at the N-terminus, C-terminus, residue 14, or residue 15.~~